Johnson & Johnson made just $502 million in global sales of its COVID-19 vaccine in the most recent quarter — falling far short of quarterly revenue from peers Pfizer and Moderna.

The pharmaceutical giant had sold just $766 million worth of the vaccine in the nine-month period that ended last month, it announced Tuesday morning along with its third-quarter earnings results.

Still, Johnson & Johnson reiterated its full-year COVID-19 vaccine sales outlook of $2.5 billion, meaning the company will need a blockbuster fourth-quarter vaccine sprint to meet its own expectations.